NCT06523465 Statin Combined with Amlodipine Treats Primary Aldosteronism
| NCT ID | NCT06523465 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Third Military Medical University |
| Condition | Primary Aldosteronism |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-09-10 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 180 participants in total. It began in 2024-09-10 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of primary aldosteronism Exclusion Criteria: * Allergy to drugs in this study * Pregnancy * Severe liver and kidney dysfunction * Mental illness
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06523465 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06523465 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06523465 currently recruiting?
Yes, NCT06523465 is actively recruiting participants. Contact the research team at sun_fang2007@163.com for enrollment information.
Where is the NCT06523465 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06523465 clinical trial?
NCT06523465 is sponsored by Third Military Medical University. The trial plans to enroll 180 participants.